Episode 104: Effects of Once-Nightly Sodium Oxybate on Narcolepsy Types 1 and 2
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Gudeman, PharmD. [LISTEN TIME: 17 minutes]
Jennifer Gudeman, PharmD
Episode 104 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 104, "Effects of Once-Nightly Sodium Oxybate on Narcolepsy Types 1 and 2" features an interview with Jennifer Gudeman, PharmD, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, who discussed a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet needs for this patient population, including lingering brain fog and overcoming negative stigmas.
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis
- ALS Candidate PrimeC Meets Primary Safety and Secondary End Points in Phase 2b PARADIGM Study
- FDA Clears NeuroOne’s OneRF Ablation System for Neurosurgerical Procedures
EPISODE BREAKDOWN
- 1:10 – Overview of post-hoc analysis of REST-ON
- 3:15 – Differences in type 1 and 2 narcolepsy
- 5:55 – Neurology News Minute
- 8:15 – Expanding treatment profile of once-nightly sodium oxybate
- 10:55 – Lingering unmet needs of patients with narcolepsy
- 11:20 – Realistic timeline of gene therapies for epilepsy
- 14:00 – Future of narcolepsy research, drug development trials
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below:
